Joined Today: 17

GILD Gilead Sciences, Stock Message Board

All Messages

GILD Message Board Home | Join The GILD Group |

#133: Gilead Announces $500 Million Accelerated Share Repurchase
TheMachine	March 3, 2008 05:09:35 AM
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it entered into an agreement with Goldman, Sachs & Co. to repurchase $500 million of its common stock under... view message ignore post recommend post

#132: GILD News Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency
NewsBot	March 23, 2007 06:00:00 AM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that GlaxoSmithKline’s Marketing Authorisation Application (MAA) for ambrisentan for the... view message ignore post recommend post

#131: GILD News SYSTIME Completes JD Edwards World Upgrade for Gilead Sciences On-Time and On-Budget
NewsBot	March 16, 2007 07:00:00 AM
SAN FRANCISCO--(BUSINESS WIRE)--SYSTIME Computer Corporation announced today the successful upgrade to Oracle’s JD Edwards World A8.1 cum 6 from A7.3 at Gilead Sciences... view message ignore post recommend post

#130: GILD News Gilead Sciences to Present at the Lehman Brothers 10th Annual Global Healthcare Conference on Monday, March 19
NewsBot	March 15, 2007 01:30:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Lehman Brothers 10th Annual Global... view message ignore post recommend post

#129: GILD News Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
NewsBot	March 15, 2007 01:15:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company will present data on a novel nucleotide analog, GS 9219, which has shown... view message ignore post recommend post

#128: GILD News Gilead Sciences Announces New Appointments within Executive Team
NewsBot	March 9, 2007 06:00:00 AM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today the appointment of Norbert W. Bischofberger, PhD to the position of Executive Vice President,... view message ignore post recommend post

#127: GILD News Gilead Sciences to Present at the Cowen & Company 27th Annual Health Care Conference on Monday, March 12
NewsBot	March 8, 2007 01:30:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Cowen and Company 27th Annual Health... view message ignore post recommend post

#126: GILD News Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
NewsBot	March 1, 2007 01:00:00 PM
LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced 24-week data from a Phase II clinical trial evaluating three doses of GS 9137 (elvitegravir), a novel... view message ignore post recommend post

#125: GILD News Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
NewsBot	February 23, 2007 01:00:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the completion of a Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor.... view message ignore post recommend post

#124: GILD News Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
NewsBot	February 16, 2007 01:00:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted a Priority... view message ignore post recommend post

#123: GILD News Carla A. Hills Joins Gilead Sciences' Board of Directors
NewsBot	January 23, 2007 05:45:00 AM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Carla A. Hills has been appointed to the company’s Board of Directors, bringing... view message ignore post recommend post

#122: GILD News Gilead Sciences to Present at the 25th Annual JPMorgan Healthcare Conference on Monday, January 8th
NewsBot	January 4, 2007 01:15:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the 25th Annual JPMorgan Healthcare ... view message ignore post recommend post

#121: GILD News Gilead Announces Preliminary Results From Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
NewsBot	December 19, 2006 01:30:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase III AIR-CF2 (CP-AI-005) study of aztreonam lysine for inhalation for the ... view message ignore post recommend post

#120: GILD News Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
NewsBot	December 18, 2006 01:15:00 PM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)... view message ignore post recommend post

#119: GILD News 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
NewsBot	December 15, 2006 05:30:00 AM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of 96-week data from an ongoing clinical trial, Study 934, in the Journal of... view message ignore post recommend post

Group Home | Login if you want to post a message